Urologia Internationalis最新文献

{"title":"Comparison of Tissue and Urine Microbiota in Male, Intervention Naive Patients with and without Non-Invasive Bladder Cancer.","authors":"Muhammed S Ozer, Canet Incir, Huseyin A Yildiz, Muslim D Deger, Alper E Sarikaya, Yesim Tuncok, Gul Ergor, Nuran Esen, Volkan Sen, Ozan Bozkurt, Adil Esen","doi":"10.1159/000541296","DOIUrl":"10.1159/000541296","url":null,"abstract":"<p><strong>Introduction: </strong>To investigate the presence of dysbiosis in patients with naive bladder cancer.</p><p><strong>Methods: </strong>Twelve male patients with non-invasive bladder cancer and twelve age-matched healthy males had midstream urine and tissue samples taken. A history of endourological interventions was determined as an exclusion criterion, ensuring that the study was designed solely with naïve participants. The bacterial 16s ribosomal RNA V3-V4 regions were used to examine urine and tissue samples. We compared the microbiota composition of the bladder cancer and control groups.</p><p><strong>Results: </strong>Escherichia Shigella (p < 0.001), Staphylococcus (p < 0.001), Delftia (p < 0.001), Acinetobacter (p < 0.001), Corynebacterium (p < 0.001), and Enhydrobacter (p < 0.001) were abundant in bladder cancer tissue samples. Escherichia Shigella (p < 0.001), Ureaplasma (p < 0.001), Lactobacillus (p = 0.005), Stenotrophomonas (p < 0.001), Streptococcus (p < 0.001), Corynebacterium (p < 0.001), and Prevotella (p = 0.039) were abundant in bladder cancer urine samples. Midstream urine has a sensitivity of 83% for detecting dysbiotic bacteria in cancer tissue.</p><p><strong>Conclusions: </strong>Our research is the first microbiota study of bladder cancer done with naive patients who have never had an endourological intervention. Escherichia Shigella, Staphylococcus, Acinetobacter, Enhydrobacter, Delftia, Corynebacterium, and Pseudomonas were detected as dysbiotic bacteria in bladder cancer. The sensitivity of the midstream urine sample in detecting dysbiosis in tissue is 83%.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"81-88"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of Lesion-Based Treatment Response after Two Cycles of Lu-177 Prostate Specific Membrane Antigen Treatment in Metastatic Castration-Resistant Prostate Cancer Using Machine Learning.","authors":"Ogün Bülbül, Demet Nak, Sibel Göksel","doi":"10.1159/000541628","DOIUrl":"10.1159/000541628","url":null,"abstract":"<p><strong>Introduction: </strong>Lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) therapy is a radionuclide treatment that prolongs overall survival in metastatic castration-resistant prostate cancer (MCRPC). We aimed to predict lesion-based treatment response after Lu-177 PSMA treatment using machine learning with texture analysis data obtained from pretreatment Gallium-68 (Ga-68) PSMA positron emission tomography/computed tomography (PET/CT).</p><p><strong>Methods: </strong>Eighty-three progressed, and 91 nonprogressed malignant foci on pretreatment Ga-68 PSMA PET/CT of 9 patients were used for analysis. Malignant foci with at least a 30% increase in Ga-68 PSMA uptake after two cycles of treatment were considered progressed lesions. All other changes in Ga-68 PSMA uptake of the lesions were considered nonprogressed lesions. The classifiers tried to predict progressed lesions.</p><p><strong>Results: </strong>Logistic regression, Naive Bayes, and k-nearest neighbors' area under the ROC curve (AUC) values in detecting progressed lesions in the training group were 0.956, 0.942, and 0.950, respectively, and their accuracy was 87%, 85%, and 89%, respectively. The AUC values of the classifiers in the testing group were 0.937, 0.954, and 0.867, respectively, and their accuracy was 85%, 88%, and 79%, respectively.</p><p><strong>Conclusion: </strong>Using machine learning with texture analysis data obtained from pretreatment Ga-68 PSMA PET/CT in MCRPC predicted lesion-based treatment response after two cycles of Lu-177 PSMA treatment.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"128-134"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibiotic Prophylaxis of Transrectal Biopsy of the Prostate: A Plea for Fosfomycin.","authors":"Philipp Julian Spachmann, Daniel Witt, Johannes Breyer, Stefan Denzinger, Maximilian Burger, Daniel Claudius Vergho, Wolfgang Otto, Marco Julius Schnabel","doi":"10.1159/000541798","DOIUrl":"10.1159/000541798","url":null,"abstract":"<p><strong>Introduction: </strong>According to guidelines, transrectal random biopsy of the prostate (TRBP) is performed under antibiotic prophylaxis (AP). Fosfomycin-trometamol (FOS) is not approved in Germany, but TRBP as indication was listed in the product information falsely. The aim was to investigate infectious complications of TRBP under FOS as a single dose.</p><p><strong>Methods: </strong>All TRBPs under FOS 3,000 mg as a single dose between July 1, 2020, and June 30, 2021, at a university institution were recorded. 357 patients (41-85 years old, median 66) were included. 243 received first TRBP, 321 TRBP were MRI-fusionated. 10-22 cores were taken (median 14). Prostate-specific antigen (PSA) was 0.1-1224 ng/mL (median 7.7 ng/mL), prostate volume 5-263 mL (median 50 mL). Analysis was performed using Chi square test or Fisher's exact test, Mann-Whitney U test, and t test.</p><p><strong>Results: </strong>Four patients suffered an infection (1.1%), without significant difference according to age (p = 0.849), PSA (p = 0.957), number of cores (p = 0.905), and increase in volume (p = 0.456). Limiting is the retrospective character.</p><p><strong>Conclusion: </strong>The complication rate was 1.1%, and FOS single dose therefore represents sufficient AP for TRBP in this collective. FOS as a single dose should be reevaluated in a prospective study to obtain approval in Germany for this indication.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"146-150"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant Therapy with Pembrolizumab in Renal Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort.","authors":"Angelika Mattigk, Cristina Cano Garcia, Niklas Klümper, Alexander Cox, Oliver Hahn, Kerstin Junker, Kati Erdmann, Philipp Schmucker, Luka Flegar, Friedemann Zengerling, Severine Banek, Jörg Ellinger, Bjoern Thorben Buerk, Johannes Huber, Charis Kalogirou, Philip Zeuschner, Benedikt Hoeh","doi":"10.1159/000543278","DOIUrl":"10.1159/000543278","url":null,"abstract":"<p><strong>Introduction: </strong>Adjuvant pembrolizumab versus placebo significantly improved disease-free survival (DFS) in renal cell carcinoma (RCC) patients at high risk (HR) of recurrence following nephrectomy in KEYNOTE-564 trial (NCT03142334). The objective of this study was to evaluate efficacy and safety of adjuvant pembrolizumab in a real-world setting.</p><p><strong>Methods: </strong>In this multicenter retrospective study, RCC patients receiving adjuvant pembrolizumab between 01/22 and 10/23 at seven tertiary referral centers were included. DFS and treatment safety were assessed.</p><p><strong>Results: </strong>Fifty-two patients with RCC were included. 24 (46%), 5 (9.6%), 22 (42%), and 1 (1.9%) patients were classified as intermediate to high risk (IR to HR), HR, M1 with no evidence of disease (M1NED), and unknown. At a median follow-up of 6 months, DFS rates at 6 months were 64.2% in the overall cohort. In subgroup analyses, M1NED patients demonstrated significantly lower DFS compared to non-metastatic (combined: IR to HR/HR) patients (log-rank: p = 0.025). Regarding toxicity, grade 3 or higher adverse events occurred in 26% of patients. Treatment discontinuations were reported in 20% of the patients.</p><p><strong>Conclusion: </strong>Recurrence rates in the M1NED group remained high and occurred earlier in our real-world compared to KEYNOTE-564. Long-term toxicities were comparable to clinical trials data.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"1-8"},"PeriodicalIF":1.5,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Time Matter in Early Radical Cystectomy? Comparing Outcome, Clinical, and Pathological Characteristics of Immediate versus Deferred Radical Cystectomy.","authors":"Yushan Yang, Sonja Holbach, Maximilian Haas, Simon Udo Engelmann, Christopher Gossler, Roman Mayr, Maximilian Burger, Johannes Breyer, Michael Gierth","doi":"10.1159/000543235","DOIUrl":"10.1159/000543235","url":null,"abstract":"<p><strong>Introduction: </strong>Early radical cystectomy (eRC) can be performed for high or very high risk non-muscle-invasive bladder cancer (NMIBC). Whether immediate eRC is beneficial is still unclear. The objective of this study was to compare outcomes between immediate eRC, delayed eRC, and radical cystectomy (RC) at the diagnosis of muscle-invasive bladder cancer (MIBC).</p><p><strong>Methods: </strong>The single-center cohort consisting of patients with RC between 2008 and 2020 was divided into 4 populations: patients who received immediate eRC within 3 months of diagnosis of NMIBC (IEC), patients who received eRC at recurrence of NMIBC (REC), patients who underwent RC after primary diagnosis of MIBC (primMIBC), and patients with the initial diagnosis of NMIBC who received RC after progression to MIBC (progMIBC).</p><p><strong>Results: </strong>Among the 463 patients included, 39 had IEC, 58 had REC, 314 had primMIBC, and 53 had progMIBC. No statistically significant differences for OS, CSS, and RFS between the two groups receiving eRC were found. Patients with pT1 tumors (p = 0.003) and tumor size ≥3 cm (p = 0.012) were more likely to receive immediate RC.</p><p><strong>Conclusion: </strong>Immediate and delayed eRC show comparable survival outcomes. The present study emphasizes the need for accurate risk stratification of patients with NMIBC to identify the most advantageous therapy for individual patients.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"1-8"},"PeriodicalIF":1.5,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discrimination of T-Stage Using Tumor Weight and Size: A Potential Approach to Guide Perioperative Decision-Making in Patients with Bladder Cancer.","authors":"Karl Tully, Henning Bahlburg, Moritz J Reike, Mirco Brehmer, Sebastian Berg, Peter Bach, Joachim Noldus, Florian Roghmann","doi":"10.1159/000543112","DOIUrl":"10.1159/000543112","url":null,"abstract":"<p><strong>Introduction: </strong>The aims of the study were to examine the value of tumor size, weight, and density in predicting pathological tumor stage in patients with suspected bladder cancer (BCa), minimize inter-observer variability of estimated tumor size, and thus provide a more objective instrument to describe the extent of local tumor growth.</p><p><strong>Methods: </strong>An institutional dataset of 588 consecutive patients undergoing transurethral resection of bladder tumor (TUR-BT) for suspected BCa from 05/2016 to 09/2018 was used. Separate Mann-Whitney U tests examined differences in each unit between non-muscle-invasive BCa (NMIBC) and muscle-invasive BCa (MIBC) and between Ta/carcinoma in situ and T1 NMIBC. Intraoperative tumor size, weight, and respective density were calculated. We then calculated multivariable logistic regression models to examine each unit's predictive value and distinguish between endpoints.</p><p><strong>Results: </strong>Overall, 367 patients undergoing TUR-BT were diagnosed with BCa. In patients with MIBC (n = 73), the median size (p < 0.001) and weight (p < 0.001) were higher compared to NMIBC. In contrast, tumor density (p < 0.001) was lower. On multivariable analysis, increasing size and weight were associated with higher odds of T1 (size: odds ratio [OR] 2.50, 95% confidence interval [CI]: 1.87-3.35; weight: OR 1.65, 95% CI: 1.26-2.15) and muscle-invasive disease (size: OR 1.51, 95% CI: 1.29-1.78; weight: OR 1.09, 95% CI: 1.03-1.15). Meanwhile, an increasing density was associated with lower odds of both outcomes (T1: OR 0.96, 95% CI: 0.89-1.02; MIBC: OR 0.81, 95% CI: 0.69-0.96).</p><p><strong>Conclusion: </strong>In patients diagnosed with BCa, tumor size, and weight showed similar predictive power concerning T1 NMIBC and MIBC. Tumor density failed to predict the local tumor stage sufficiently. These results may lay the foundation for improving objective measurement of the local tumor burden in patients with BCa and may help guide further immediate treatment decisions.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"1-7"},"PeriodicalIF":1.5,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Surgical Therapy for Local Recurrence and Oligometastatic Urothelial Carcinoma of the Bladder: 20 Years of Experience in a Tertiary Center.","authors":"Mulham Al-Nader, Ulrich Krafft, Christopher Darr, Jochen Heß, Claudia Kesch, Lukas Püllen, Stephan Tschirdewahn, Umut-Ulas Yesilyurt, Aykhan Isgandarov, Boris Hadaschik, Osama Mahmoud","doi":"10.1159/000542982","DOIUrl":"10.1159/000542982","url":null,"abstract":"<p><strong>Introduction: </strong>The impact of surgical therapy on selected patients with limited metastatic/recurrence burden has not yet been well studied. We investigated the outcome of surgical resection for patients with local recurrence only or oligometastatic urothelial carcinoma (UC) of the bladder.</p><p><strong>Methods: </strong>We identified patients with oligometastatic UC or local recurrence only after radical cystectomy who underwent surgical resection with curative intent between 2003 and 2022 at our center. Oligometastatic UC was defined as three or fewer resectable lesions, regardless of the number of organs involved. We studied the surgical outcome, progression-free survival (PFS) and overall survival (OS) in this selected group of patients.</p><p><strong>Results: </strong>A total of 39 patients were selected, including 18 (46%) with local recurrence and 21 (54%) with oligometastatic UC. Nine patients (23%) experienced intraoperative complications, all of whom belonged to the local recurrence group, while 8 patients (20.5%) experienced major postoperative complications, including 6 patients from the local recurrence group and 2 patients with oligometastatic disease. The median PFS following surgery was 19 months (95% CI; 2.5-35.5) with 1- and 3-year progression rates of 47% and 29%, while the median OS was 24 months (95% CI; 8.6-39.3) with 1- and 3-year survival rates of 51% and 30%. A significantly better median PFS was observed in the metastatic versus local recurrence group (35 vs. 8 months, p = 0.01). Similarly, a median OS of 41 months was observed in the metastatic group compared to only 12 months for the local recurrence group (p = 0.12). Overall, a better survival time of 30 months was observed in the metachronous group compared to 6 months in the synchronous group (p = 0.046). In a further analysis of the metastatic group, metachronous oligometastasis was associated with a longer survival of 43 months compared to 9 months for synchronous metastasis (p = 0.18). Some differences were not significant, which may be due to sample size.</p><p><strong>Conclusion: </strong>Our study shows reasonable surgical and survival outcomes of metastasectomy, especially in the metachronous subgroup, for UC without risk of higher perioperative morbidity. On the other hand, resection of local recurrence is associated with a higher risk of incomplete resection and higher intraoperative and postoperative morbidity without offering a survival benefit.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"1-9"},"PeriodicalIF":1.5,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of diabetes and antidiabetics on the obesity paradox in renal cell cancer.","authors":"Moustafa Elleisy, Heike Zettl, Desiree Louise Dräger, Oliver W Hakenberg","doi":"10.1159/000543072","DOIUrl":"https://doi.org/10.1159/000543072","url":null,"abstract":"","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"1-4"},"PeriodicalIF":1.5,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Analysis of Renal and Surgical Outcomes of Patients with and without Preoperative Ureteral Stenting before Nephron-Sparing Surgery for Renal Malignancies of Higher Complexity by Using a Propensity Score-Based Approach.","authors":"Marcel Schwinger, Johanna Wege, Oliver Hahn, Hubert Kübler, Vincent Scheper, Charis Kalogirou","doi":"10.1159/000543073","DOIUrl":"10.1159/000543073","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to evaluate the impact of preoperative ureteral stenting on post-operative outcomes, especially the incidence of urinoma, in patients with complex renal tumours undergoing nephron-sparing surgery (NSS).</p><p><strong>Methods: </strong>A retrospective analysis of 35 patients received preoperative ureteral stenting prior to NSS for complex tumours at the University Hospital of Würzburg between 2002 and 2021. A control group of 115 patients was established through 1:3 propensity score matching based on age, gender, T-stage, and RENAL score. Clinical parameters, surgical outcomes, and complications were assessed, and statistical comparisons were performed using the unpaired Student's t test and chi-square test.</p><p><strong>Results: </strong>While both groups showed comparable tumour complexity (RENAL: 7 vs. 7, p = 0.58; PADUA: 9 vs. 8, p = 0.62), there were no significant differences in median hospital stay (12 vs. 11; p = 0.068), surgical time (183 vs. 190 min; p = 0.37), post-operative haemoglobin levels (11 g/dL vs. 11.1 day/dL; p = 0.9), and renal function (GFR 65 mL/min/m2 in both groups). Moreover complication severity during NSS, defined by Clavien-Dindo classification, was similar (none vs. grade I; p = 0.29). No significant difference in the rate of urinoma was observed (11% vs. 4%, p = 0.93).</p><p><strong>Conclusions: </strong>This study found no significant benefits of preoperative ipsilateral ureteral stenting on post-operative outcomes, particularly concerning the development of urinoma. Given these findings, preventive ureteral stenting is not recommended prior to partial kidney resection for complex renal tumours.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"1-7"},"PeriodicalIF":1.5,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Ureteral Access Sheaths on Radiation Exposure in the Ureterorenoscopic Treatment of Urolithiasis.","authors":"Lennert Eismann, Severin Rodler, Alexander Buchner, Frank Strittmatter, Abdulmajeed Alghamdi, Simon Lennartz, Jan-Peter Grunz, Raphaela Waidelich, Armin Becker, Philipp Weinhold, Alexander Kretschmer, Christian G Stief, Thilo Westhofen","doi":"10.1159/000542945","DOIUrl":"10.1159/000542945","url":null,"abstract":"<p><strong>Introduction: </strong>Ureteral access sheaths (UASs) are widely used in the endoscopic treatment of urolithiasis. In modern medicine, radiation exposure from diagnostics and therapy is increasing; however, the impact of UAS on procedure duration, fluoroscopy time, and radiation exposure is still uncertain.</p><p><strong>Methods: </strong>This retrospective study included 1,026 patients who received ureterorenoscopic treatment for nephrolithiasis between 2016 and 2018 at a large academic center. Patients were dichotomized according to the use of UAS, and propensity-score matching was performed based on age, BMI, and stone size. Patient demographics, stone size, radiographic density, perioperative complications, and postoperative outcome were assessed. Procedure time and radiation exposure, recorded as the fluoroscopy time and area dose product, were analyzed.</p><p><strong>Results: </strong>In total, 300 patients were successfully matched to the cohort with UAS (n = 150) and the cohort without UAS (n = 150). Patients' demographics were similar for age, gender, BMI, and ASA score (each p > 0.05). Median stone size was 8 mm and 7.5 mm in the cohort with and without UAS (p = 0.335). Procedure time showed no differences between the two cohorts (p = 0.749). Fluoroscopy time and area dose product were significantly lower in patients treated with the use of UAS (p = 0.004; p < 0.001).</p><p><strong>Conclusion: </strong>The use of a UAS does not prolong operation time in patients with an equivalent stone burden. In addition, the use of a UAS reduces fluoroscopy time and radiation exposure. In the future, to reduce radiation exposure to the patient and medical staff, the use of a UAS should also be considered for limited stone disease.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"1-7"},"PeriodicalIF":1.5,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142795235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}